regenerative-therapeutics
(2)
Caralynn Nowinski Collens
Caralynn Nowinski Collens is a physician-turned-entrepreneur and the co-founder and CEO of Dimension Bio (formerly Dimension Inx), a Chicago biotechnology company building regenerative therapeutics that give the body a blueprint to heal itself. Its BioNidum platform fuses materials science, 3D-printing, and digital manufacturing to turn cells into implantable, tissue-like therapies. Before biotech, she spent eight years co-founding and running UI LABS, the innovation collaborative that launched MxD, the U.S. national hub for digital manufacturing. She trained as an M.D./MBA at the University of Illinois at Chicago and has been recognized on Crain's Forty Under Forty, Tech 50, and Notable Women in STEM lists.
Dimension Bio
Dimension Bio (formerly Dimension Inx) is a Chicago-based regenerative therapeutics company that turns living cells into implantable, tissue-like therapies. Its BioNidum platform fuses materials science, 3D printing, and digital manufacturing to build three-dimensional microenvironments that help transplanted cells survive, vascularize, and function in the body. A Northwestern University spinout, the company already brought the first FDA-cleared 3D-printed regenerative bone graft (CMFlex) to patients and is now aiming its lead program at acute liver failure - building an engineered, mini-liver-like therapy to stabilize patients and give their own organs a chance to recover.